D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial.
Orphanet J Rare Dis
; 16(1): 138, 2021 03 20.
Article
em En
| MEDLINE
| ID: mdl-33743737
ABSTRACT
PMM2-CDG is the most prevalent congenital disorder of glycosylation (CDG) with only symptomatic therapy. Some CDG have been successfully treated with D-galactose. We performed an open-label pilot trial with D-galactose in 9 PMM2-CDG patients. Overall, there was no significant improvement but some milder patients did show positive clinical changes; also there was a trend toward improved glycosylation. Larger placebo-controlled studies are required to determine whether D-galactose could be used as supportive treatment in PMM2-CDG patients.Trial registration ClinicalTrials.gov Identifier NCT02955264. Registered 4 November 2016, https//clinicaltrials.gov/ct2/show/NCT02955264.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fosfotransferases (Fosfomutases)
/
Defeitos Congênitos da Glicosilação
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article